(1)

Regulation (EU) 2016/429 lays down disease-specific rules for the diseases listed in accordance with Article 5(1) thereof and lays down how those rules are to be applied to different categories of listed diseases. Regulation (EU) 2016/429 provides for the Member States to establish compulsory eradication programmes for the listed diseases referred to in Article 9(1), point (b), thereof, and for optional eradication programmes for listed diseases referred to in Article 9(1), point (c), thereof, and for the approval of such programmes by the Commission. That Regulation also provides for the approval or withdrawal by the Commission of the disease-free status of Member States or zones or compartments thereof regarding certain listed diseases referred to in Article 9(1), points (b) and (c), thereof.

(2)

Commission Delegated Regulation (EU) 2020/689 (2) supplements Regulation (EU) 2016/429 and lays down the criteria for granting, maintaining, suspending, and withdrawing disease-free status for Member States or zones or compartments thereof, and the requirements for the approval of compulsory or optional eradication programmes for Member States or zones or compartments thereof.

(3)

Commission Implementing Regulation (EU) 2021/620 (3) lays down implementing rules for the listed diseases, referred to in Article 9(1), points (a), (b) and (c), of Regulation (EU) 2016/429, of animals, as regards the disease-free and non-vaccination status of certain Member States or zones or compartments thereof, and the approval of eradication programmes for those listed diseases. More particularly, it lists in the Annexes thereto, the Member States or zones or compartments thereof with disease-free status, and it also lists the existing approved compulsory or optional eradication programmes. The changing epidemiological situation of the Aujeszky’s disease virus (ADV) and the bluetongue virus (serotypes 1-24) (BTV) in certain Member States makes it necessary to amend Annexes VI and VIII to Implementing Regulation (EU) 2021/620 to reflect the current situation.

(4)

For infection with ADV and infection with BTV, certain Member States have recently applied to the Commission to have disease-free status granted or optional eradication programmes approved for certain zones of their territory. Certain Member States have also notified outbreaks of infection with BTV. Accordingly, this situation should be reflected in Annexes VI and VIII to Implementing Regulation (EU) 2021/620.

(5)

For infection with ADV, Portugal has submitted to the Commission information demonstrating that the conditions for the recognition of disease-free status from infection with ADV laid down in Delegated Regulation (EU) 2020/689 are fulfilled for the Autonomous Region of the Azores. Following the assessment by the Commission, that application has been shown to comply with the criteria laid down in Part II, Chapter 4, of Delegated Regulation (EU) 2020/689 for the granting of disease-free status from infection with ADV. Therefore, that zone should be listed in Part I of Annex VI to Implementing Regulation (EU) 2021/620, as having disease-free status from infection with ADV.

(6)

As regards infection with BTV, Belgium and the Netherlands have notified to the Commission several outbreaks of infection with BTV serotype 3 affecting the whole territory of those Member States, Germany has notified to the Commission an outbreak of infection with BTV serotype 3 affecting the state of North Rhine-Westphalia, and Spain has notified to the Commission several outbreaks of infection with BTV serotype 4 in the province of Ciudad Real in the Autonomous Community of Castilla-La Mancha, also affecting the surrounding provinces of Albacete, Cuenca and Toledo. As the whole territory of Belgium, the whole territory of Germany, the whole territory of the Netherlands, and parts of those provinces in Spain are recognised as having disease-free status and are listed in Part I of Annex VIII to Implementing Regulation (EU) 2021/620, such disease-free status from infection with BTV should be withdrawn, and the entries for the whole territory of Belgium and for the whole territory of the Netherlands should be deleted, and the entries for Germany and for Spain in that list should be amended accordingly.

(7)

As regards infection with BTV, Spain has also informed the Commission that it has extended the territorial scope of the optional eradication programme already approved for the zone listed in Part II of Annex VIII to Implementing Regulation (EU) 2021/620 with the addition of a zone comprising the whole of the provinces of Albacete, Ciudad Real and Toledo in the Autonomous Community of Castilla-La Mancha. Therefore, that zone should be added to the entry for Spain in Part II of Annex VIII to Implementing Regulation (EU) 2021/620, as a zone with an approved eradication programme for infection with BTV.

(8)

Annexes VI and VIII to Implementing Regulation (EU) 2021/620 should, therefore, be amended accordingly.

(9)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,